JSMC-10399

THE WEIGHT-REDUCING EFFECT OF ENDOSCOPICALLY–INSERTED INTRAGASTRIC BALLOONS FOR OBESE PATIENTS FAILED WEIGHT CONTROL WITH LIFESTYLE MODIFICATION AND DRUGS

Hiwa Abubakr Hussein a, Bakhtyar Faiq Salim a, Mohammad Abdul Rahman Al-Shaikhani a, and Aziz Qadir Sleman b

 Submitted: 19/5/2019; Accepted: 8/3/2023; Published: 21/3/2023

a College of Medicine. University of Sulaimani, Kurdistan Region, Iraq. 

b Directorate of Health of Sulaimani, Ministry of Health. Kurdistan Region. Iraq.

DOI Link: https://doi.org/10.17656/jsmc.10399 

---------------------------------------------------------------------------------------------------------------------------------------------------------------

ABSTRACT

Background 

The Food and Drug Administration (FDA) recently approved three intragastric balloons (IGB) devices, ReShape, ORBERA™, and Obalon, for treating obesity. Given the high cost, complication risk, and invasiveness of bariatric surgery, IGB treatment may present a safer and lower-cost option for weight reduction. IGBs are generally placed in the stomach endoscopically for up to 6 months to reduce gastric capacity, enhance feelings of fullness, and induce weight loss. The mechanism of action likely involves stimulation of gastric mechanoreceptors triggering short-acting vagal signals to brain regions implicated in satiety. Balloon efficacy may be influenced by balloon volume, patient gastric capacity, and treatment duration.

Objectives 

To evaluate the efficacy, tolerability, and safety of intra-gastric balloons on weight reduction versus obese patients’ failed weight controlled by dietary changes and drugs.

Methods

A retrospective study was performed in Sulaimani City from 2017 to Feb./2018. We included 40 obese patients by the World Health Organization (WHO) definition of BMI≥30. The subjects aged 18-68 years with intra-gastric balloons were inserted by endoscopy for 4-9 months. Anthropometric measurements were obtained before, during and after the removal of intra-gastric balloons.

Results

In total, 40 cases of obese patients, 21 (52.5%) females and 19 (47.5%) males. The mean age was 37.1±11.70years with a range of 18-68 years. BMI and weight significantly reduced early 3-month mean weight 12.78±2.81 Kg, and late 6-month mean weight 9.05±1.89 Kg and around 21 Kgs at removal. Only one patient was the IGB removed early by four months and was not included. Late one year after IGB removal, the long-term effect on BMI and weight were recorded and maintained in most persons. 

Conclusion

Intragastric balloon (IGB) was effective in our study. The observed weight reduction was maintained through 1 year after removal & IGB appeared safe and tolerable & satisfactory for most obese subjects.

KEYWORDS

Intragastric balloon, Obesity, Weight reduction, Body mass index.

References 

1. American College of Physicians (2003- ), editor. MKSAP 17: medical knowledge self-assessment program. Philadelphia, Pa: American College of Physicians; 2015.  

2. Walker BR, Colledge NR, Ralston S, Penman ID, Britton R, editors. Davidson’s principles and practice of medicine. 22nd edition. Edinburgh; New York: Churchill Livingstone/Elsevier; 2014. 1372 p. 

3. Laing P, Pham T, Taylor LJ, Fang J. Filling the Void: A Review of Intragastric Balloons for Obesity. Dig Dis Sci. 2017 Jun;62(6):1399–408. 

4. Faris A. K. Khazaal AHL, Insaf Jasim, Zidan alhergani Weight loss program outcome of obese attending AL-Kindy obesity research and therapy unit. Al-Kindy Coll Med J 2015;11(1):21–4. 

5. The GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017 Jul 6;377(1):13–27. 

6. Papadakis MA, McPhee SJ, Rabow MW. Current medical diagnosis & treatment 2017 [Internet]. 2017 [cited 2018 Feb 27]. Available from: http://accessmedicine.mhmedical.com/book.aspx?bookid=1843

7. Borges AC, Almeida PC, Furlani SMT, Cury MDS, Gaur S. Intragastric balloons in high-risk obese patients in a Brazilian centre: initial experience. Rev Colégio Bras Cir [Internet]. 2018 Feb 15 [cited 2018 Mar 1];45(1). Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912018000100155&lng=en&tlng=en

8. Eckel RH. Nonsurgical Management of Obesity in Adults. N Engl J Med. 2008 May;358(18):1941–50. 

9. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. Longo DL, editor. N Engl J Med. 2017 Jan 19;376(3):254–66. 

10. Fisher BL, Schauer P. Medical and surgical options in the treatment of severe obesity. Am J Surg. 2002 Dec;184(6B):9S–16S. 

11. Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007 Oct;107(10):1755–67. 

12. Avenell A, Brown TJ, McGee MA, Campbell MK, Grant AM, Broom J, et al. What are the long-term benefits of weight-reducing diets in adults? A systematic review of randomised controlled trials. J Hum Nutr Diet Off J Br Diet Assoc. 2004 Aug;17(4):317–35. 

13. Almeghaiseeb ES, Ashraf MF, Alamro RA, Almasoud AO, Alrobayan AA. Efficacy of intragastric balloon on weight reduction: Saudi perspective. World J Clin Cases. 2017;5(4):140. 

14. Benjamin IJ, Griggs RC, Wing EJ, Fitz JG, editors. Andreoli and Carpenter’s Cecil essentials of medicine. 9th edition. Philadelphia, PA: Elsevier/Saunders; 2016. 1190 p. 

15. Guedes EP, Madeira E, Mafort TT, Madeira M, Moreira RO, de Mendonça LMC, et al. Impact of 6 months of treatment with the intragastric balloon on body fat and quality of life in obese individuals with metabolic syndrome. Health Qual Life Outcomes [Internet]. 2017 Dec [cited 2018 Mar 2];15(1). Available from: http://hqlo.biomedcentral.com/articles/10.1186/s12955-017-0790-x

16. Kumar N, Sullivan S, Thompson C. The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy. Diabetes Metab Syndr Obes Targets Ther. 2017 Jul; Volume 10:311–6. 

17. Mathus-Vliegen EMH. Is Endoscopy Really Necessary for Placing Intragastric Balloons? Obes Surg. 2018 Jan;28(1):169–75. 

18. Gleysteen JJ. A history of intragastric balloons. Surg Obes Relat Dis. 2016 Feb;12(2):430–5. 

19. Gaur S, Levy S, Mathus-Vliegen L, Chuttani R. Balancing risk and reward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc. 2015 Jun;81(6):1330–6. 

20. Genco A, Cipriano M, Materia A, Bacci V, Maselli R, Musmeci L, et al. Laparoscopic sleeve gastrectomy versus intragastric balloon: a case-control study. Surg Endosc. 2009 Aug;23(8):1849–53. 

21. Roman S, Napoléon B, Mion F, Bory R-M, Guyot P, D’Orazio H, et al. Intragastric Balloon for “Non-Morbid” Obesity: A Retrospective Evaluation of Tolerance and Efficacy. Obes Surg. 2004 Apr 1;14(4):539–44. 

22. Genco A, Cipriano M, Bacci V, Cuzzolaro M, Materia A, Raparelli L, et al. BioEnterics® Intragastric Balloon (BIB®): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006 Jan;30(1):129–33. 

23. Issam Merdan. ORBERATM INTRAGASTRIC BALLOON SYSTEM. Basrah J Surgy, 2015 .;21(2):3–6. 

24. Genco A, Bruni T, Doldi SB, Forestieri P, Marino M, Busetto L, et al. BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients. Obes Surg. 2005 Sep 1;15(8):1161–4. 

25. Dumonceau J-M. Evidence-based Review of the Bioenterics Intragastric Balloon for Weight Loss. Obes Surg. 2008 Dec;18(12):1611–7. 

26. Abdel-Salam WN, Bekheit M, Katri K, Ezzat T, El Kayal ES. Efficacy of Intragastric Balloon in Obese Egyptian Patients and the Value of Extended Liquid Diet Period in Mounting the Weight Loss. J Laparoendosc Adv Surg Tech. 2013 Mar;23(3):220–4. 

27. Coskun H, Bostanci O, Dilege E, Bozbora A. BioEnterics Intragastric Balloon: Clinical Outcomes of the First 100 Patients—A Turkish Experience. Obes Surg. 2008 Sep;18(9):1154–6. 

28. Herve J, Wahlen CH, Schaeken A, Dallemagne B, Dewandre JM, Markiewicz S, et al. What Becomes of Patients One Year after the Intragastric Balloon has been Removed? Obes Surg. 2005 Jun 1;15(6):864–70. 

29. Mathus-Vliegen EMH, Tytgat GNJ. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005 Jan;61(1):19–27. 

sitive Parenting and Child Social Competence. Child, Care, Health and Development, (2011); 24(3): 524–532.

Full Text